About: Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin)

Documentation

scienceplus.abes.fr version Bêta

scienceplus.abes.fr | explorer

À propos de : Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin) Goto Sponge NotDistinct Permalink

Attributs	Valeurs
type	work Article
Is Part Of	http://hub.abes.fr/bmj/periodical/jme/2011/volume_38/issue_3/w
Subject	drugs and drug industry international affairs Press releases Bioethics BRIEF REPORT chemical and biological weapons
Title	Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin)
has manifestation of work	http://hub.abes.fr/bmj/periodical/jme/2011/volume_38/issue_3/B35AFFC02C2E606BE053120B220AE7C1/m/print http://hub.abes.fr/bmj/periodical/jme/2011/volume_38/issue_3/B35AFFC02C2E606BE053120B220AE7C1/m/web
related by	http://hub.abes.fr/bmj/periodical/jme/2011/volume_38/issue_3/B35AFFC02C2E606BE053120B220AE7C1/authorship/1 http://hub.abes.fr/bmj/periodical/jme/2011/volume_38/issue_3/B35AFFC02C2E606BE053120B220AE7C1/authorship/2 http://hub.abes.fr/bmj/periodical/jme/2011/volume_38/issue_3/B35AFFC02C2E606BE053120B220AE7C1/authorship/3 http://hub.abes.fr/bmj/periodical/jme/2011/volume_38/issue_3/B35AFFC02C2E606BE053120B220AE7C1/authorship/4
Abstract	There are several good reasons for the UK Department of Health to recommend the appraisal of bevacizumab for the treatment of eye conditions by the National Institute for Health and Clinical Excellence. These reasons will extend to other drugs when similar situations arise in the future.
article type	brief-report
publisher identifier	medethics-2011-100032
is part of this journal	Journal of Medical Ethics
PubMed ID	21947806

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata